Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Promoting effects of the adipokine, apelin, on diabetic nephropathy.

Zhang BH, Wang W, Wang H, Yin J, Zeng XJ.

PLoS One. 2013;8(4):e60457. doi: 10.1371/journal.pone.0060457. Epub 2013 Apr 5.

2.

Cardioprotective effects of adipokine apelin on myocardial infarction.

Zhang BH, Guo CX, Wang HX, Lu LQ, Wang YJ, Zhang LK, Du FH, Zeng XJ.

Heart Vessels. 2014 Sep;29(5):679-89. doi: 10.1007/s00380-013-0425-z. Epub 2013 Oct 19.

PMID:
24141989
3.

Apelin enhances cardiac neovascularization after myocardial infarction by recruiting aplnr+ circulating cells.

Tempel D, de Boer M, van Deel ED, Haasdijk RA, Duncker DJ, Cheng C, Schulte-Merker S, Duckers HJ.

Circ Res. 2012 Aug 17;111(5):585-98. doi: 10.1161/CIRCRESAHA.111.262097. Epub 2012 Jul 2.

4.

Apelin promotes diabetic nephropathy by inducing podocyte dysfunction via inhibiting proteasome activities.

Guo C, Liu Y, Zhao W, Wei S, Zhang X, Wang W, Zeng X.

J Cell Mol Med. 2015 Sep;19(9):2273-85. doi: 10.1111/jcmm.12619. Epub 2015 Jun 23.

5.

Inducible overexpression of sFlt-1 in podocytes ameliorates glomerulopathy in diabetic mice.

Ku CH, White KE, Dei Cas A, Hayward A, Webster Z, Bilous R, Marshall S, Viberti G, Gnudi L.

Diabetes. 2008 Oct;57(10):2824-33. doi: 10.2337/db08-0647. Epub 2008 Jul 22.

6.

Apelin retards the progression of diabetic nephropathy.

Day RT, Cavaglieri RC, Feliers D.

Am J Physiol Renal Physiol. 2013 Mar 15;304(6):F788-800. doi: 10.1152/ajprenal.00306.2012. Epub 2013 Jan 9.

7.

Transgenic overexpression of GLUT1 in mouse glomeruli produces renal disease resembling diabetic glomerulosclerosis.

Wang Y, Heilig K, Saunders T, Minto A, Deb DK, Chang A, Brosius F, Monteiro C, Heilig CW.

Am J Physiol Renal Physiol. 2010 Jul;299(1):F99-F111. doi: 10.1152/ajprenal.00466.2009. Epub 2010 Apr 7.

8.

Propyl gallate plays a nephroprotective role in early stage of diabetic nephropathy associated with suppression of glomerular endothelial cell proliferation and angiogenesis.

Tian S, Tang J, Liu H, Wang L, Shen J, Li J, Gan Y.

Exp Diabetes Res. 2012;2012:209567. doi: 10.1155/2012/209567. Epub 2012 Sep 4.

9.

Simvastatin alleviates hyperpermeability of glomerular endothelial cells in early-stage diabetic nephropathy by inhibition of RhoA/ROCK1.

Peng H, Luo P, Li Y, Wang C, Liu X, Ye Z, Li C, Lou T.

PLoS One. 2013 Nov 14;8(11):e80009. doi: 10.1371/journal.pone.0080009. eCollection 2013.

10.

Glomerular VEGF resistance induced by PKCδ/SHP-1 activation and contribution to diabetic nephropathy.

Mima A, Kitada M, Geraldes P, Li Q, Matsumoto M, Mizutani K, Qi W, Li C, Leitges M, Rask-Madsen C, King GL.

FASEB J. 2012 Jul;26(7):2963-74. doi: 10.1096/fj.11-202994. Epub 2012 Apr 12.

11.

Gene expression profiling in glomeruli from human kidneys with diabetic nephropathy.

Baelde HJ, Eikmans M, Doran PP, Lappin DW, de Heer E, Bruijn JA.

Am J Kidney Dis. 2004 Apr;43(4):636-50.

PMID:
15042541
12.

Vascular endothelial growth factor in diabetic nephropathy.

Lenz T, Haak T, Malek J, Gröne HJ, Geiger H, Gossmann J.

Kidney Blood Press Res. 2003;26(5-6):338-43.

13.

A role for endothelial cells in promoting the maturation of astrocytes through the apelin/APJ system in mice.

Sakimoto S, Kidoya H, Naito H, Kamei M, Sakaguchi H, Goda N, Fukamizu A, Nishida K, Takakura N.

Development. 2012 Apr;139(7):1327-35. doi: 10.1242/dev.072330. Epub 2012 Feb 22.

14.
15.

Plasma and urinary vascular endothelial growth factor and diabetic nephropathy in Type 2 diabetes mellitus.

Kim NH, Kim KB, Kim DL, Kim SG, Choi KM, Baik SH, Choi DS, Kang YS, Han SY, Han KH, Ji YH, Cha DR.

Diabet Med. 2004 Jun;21(6):545-51.

PMID:
15154937
16.

Glomerular expression of platelet-derived growth factor (PDGF)-A, -B chain and PDGF receptor-alpha, -beta in human diabetic nephropathy.

Uehara G, Suzuki D, Toyoda M, Umezono T, Sakai H.

Clin Exp Nephrol. 2004 Mar;8(1):36-42.

PMID:
15067514
18.

Apelin gene therapy increases myocardial vascular density and ameliorates diabetic cardiomyopathy via upregulation of sirtuin 3.

Zeng H, He X, Hou X, Li L, Chen JX.

Am J Physiol Heart Circ Physiol. 2014 Feb 15;306(4):H585-97. doi: 10.1152/ajpheart.00821.2013. Epub 2013 Dec 20.

19.

Analysis of NO-synthase expression and clinical risk factors in human diabetic nephropathy.

Hohenstein B, Hugo CP, Hausknecht B, Boehmer KP, Riess RH, Schmieder RE.

Nephrol Dial Transplant. 2008 Apr;23(4):1346-54. Epub 2007 Dec 9.

PMID:
18065828
20.

Vascular endothelial growth factor (VEGF) and VEGF receptors in diabetic nephropathy: expression studies in biopsies of type 2 diabetic patients.

Bortoloso E, Del Prete D, Gambaro G, Dalla Vestra M, Sailer A, Baggio B, Antonucci F, Fioretto P, Anglani F.

Ren Fail. 2001 May-Jul;23(3-4):483-93.

PMID:
11499563

Supplemental Content

Support Center